Back to News
Market Impact: 0.15
Biohaven Gains As SK Biopharma Licenses Kv7 Epilepsy Platform In Global Deal
Source: Nasdaq
Healthcare & BiotechPatents & Intellectual PropertyM&A & Restructuring
Biohaven (BHVN) announced a global licensing agreement with SK Biopharmaceuticals (326030.KS). The article does not disclose deal economics or any near-term financial impact, so the update appears more informational than market-moving absent additional terms.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.05
Ticker Sentiment
BHVN0.35
More News
- IonQ's Biggest Move Yet: A $1.3B Security Acquisition
- Starbucks says it is not buying Chipotle after takeover speculation
- UnitedHealth shares are doing something unusual ahead of earnings
- AstraZeneca at ASBMR 2026: rare disease push hinges on new bone drug
- IonQ to buy cybersecurity firm Elisity for up to $1.3bn in stock
- Banks Poised to Surprise Wall Street: Analyst